STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today
that it will host a conference call to discuss its fiscal 2020
second quarter financial results at 10:00 a.m. Eastern Time on
Tuesday, November 5, 2019. The conference call can be heard
live over the Internet at www.steris-ir.com or via phone by dialing
1-833-535-2199 in the United States or 1-412-902-6776
internationally, then asking to join the conference call for STERIS
plc.
A press release detailing second quarter financial results will
be issued after the U.S. market closes on November 4,
2019.
For those unable to listen to the conference call live, a replay
will be available beginning at 12:00 p.m. Eastern Time on November
5, 2019, either over the Internet at www.steris-ir.com or via
phone. To access the replay of the call, please use the
access code 10136019 and dial 1-877-344-7529 in the United States
or 1-412-317-0088 internationally.
About STERIS
STERIS’s mission is to HELP OUR CUSTOMERS CREATE A HEALTHIER AND
SAFER WORLD by providing innovative healthcare and life science
product and service solutions around the globe. For more
information, visit www.steris.com.
Investor Contact:
Julie Winter, Senior Director, Investor Relations and Corporate
Communications
Julie_Winter@steris.com
+1.440.392.7245
Media Contact:
Stephen Norton, Senior Director, Corporate Communications
Stephen_Norton@steris.com
+1.440.392.7482
Forward-Looking StatementsThis release and the
referenced conference call may contain statements concerning
certain trends, expectations, forecasts, estimates, or other
forward-looking information affecting or relating
to STERIS or its industry, products or activities that
are intended to qualify for the protections afforded
“forward-looking statements” under the Private Securities
Litigation Reform Act of 1995 and other laws and regulations.
Forward-looking statements speak only as to the date the statement
is made and may be identified by the use of forward-looking terms
such as “may,” “will,” “expects,” “believes,” “anticipates,”
“plans,” “estimates,” “projects,” “targets,” “forecasts,”
“outlook,” “impact,” “potential,” “confidence,” “improve,”
“optimistic,” “deliver,” “orders,” “backlog,” “comfortable,”
“trend”, and “seeks,” or the negative of such terms or other
variations on such terms or comparable terminology. Many important
factors could cause actual results to differ materially from those
in the forward-looking statements including, without limitation,
disruption of production or supplies, changes in market conditions,
political events, pending or future claims or litigation,
competitive factors, technology advances, actions of regulatory
agencies, and changes in laws, government regulations, labeling or
product approvals or the application or interpretation thereof.
Other risk factors are described in STERIS’s other securities
filings, including Item 1A of our Annual Report on Form 10-K
for the year ended March 31, 2019. Many of these important factors
are outside of STERIS’s control. No assurances can be provided as
to any result or the timing of any outcome regarding matters
described in STERIS’s securities filings or otherwise with respect
to any regulatory action, administrative proceedings, government
investigations, litigation, warning letters, cost reductions,
business strategies, earnings or revenue trends or future financial
results. References to products are summaries only and should not
be considered the specific terms of the product clearance or
literature. Unless legally required, STERIS does not
undertake to update or revise any forward-looking statements even
if events make clear that any projected results, express or
implied, will not be realized. Other potential risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements include, without
limitation, (a) STERIS's ability to achieve the expected benefits
regarding the accounting and tax treatments of the Redomiciliation
transaction, (b) operating costs, Customer loss and business
disruption (including, without limitation, difficulties in
maintaining relationships with employees, Customers, clients or
suppliers) being greater than expected following the
Redomiciliation, (c) STERIS’s ability to meet expectations
regarding the accounting and tax treatment of the Tax Cuts and Jobs
Act (“TCJA”) or the possibility that anticipated benefits resulting
from the TCJA will be less than estimated, (d) changes in tax
laws or interpretations that could increase our consolidated tax
liabilities, including changes in tax laws that would result in
STERIS being treated as a domestic corporation for United States
federal tax purposes, (e) the potential for increased pressure
on pricing or costs that leads to erosion of profit margins,
(f) the possibility that market demand will not develop for
new technologies, products or applications or services, or business
initiatives will take longer, cost more or produce lower benefits
than anticipated, (g) the possibility that application of or
compliance with laws, court rulings, certifications, regulations,
regulatory actions, including without limitation those relating to
FDA warning notices or letters, government investigations, the
outcome of any pending FDA requests, inspections or submissions, or
other requirements or standards may delay, limit or prevent new
product introductions, affect the production and marketing of
existing products or services or otherwise affect STERIS’s
performance, results, prospects or value, (h) the potential of
international unrest, economic downturn or effects of currencies,
tax assessments, tariffs and/or other trade barriers, adjustments
or anticipated rates, raw material costs or availability, benefit
or retirement plan costs, or other regulatory compliance costs,
(i) the possibility of reduced demand, or reductions in the
rate of growth in demand, for STERIS’s products and services,
(j) the possibility of delays in receipt of orders, order
cancellations, or delays in the manufacture or shipment of ordered
products or in the provision of services, (k) the possibility
that anticipated growth, cost savings, new product acceptance,
performance or approvals, or other results may not be achieved, or
that transition, labor, competition, timing, execution, regulatory,
governmental, or other issues or risks associated with STERIS’s
businesses, industry or initiatives including, without limitation,
those matters described in our Annual Report on Form 10-K for the
year ended March 31, 2019, and other securities filings, may
adversely impact STERIS’s performance, results, prospects or value,
(l) the impact on STERIS and its operations, or tax
liabilities, of Brexit or the exit of other member countries from
the EU, and the Company’s ability to respond to such impacts,
(m) the impact on STERIS and its operations of any
legislation, regulations or orders, including but not limited to
any new trade or tax legislation, regulations or orders, that may
be implemented by the U.S. administration or Congress, or of any
responses thereto, (n) the possibility that anticipated
financial results or benefits of recent acquisitions, or of
STERIS’s restructuring efforts, or of recent divestitures, or of
the targeted restructuring plan will not be realized or will be
other than anticipated, and (o) the effects of contractions in
credit availability, as well as the ability of STERIS’s Customers
and suppliers to adequately access the credit markets when
needed.
STERIS (NYSE:STE)
Historical Stock Chart
From Aug 2024 to Sep 2024
STERIS (NYSE:STE)
Historical Stock Chart
From Sep 2023 to Sep 2024